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Background: Healing after myocardial infarction (MI) involves the biphasic accumulation of 
inflammatory Ly-6Chigh and reparative Ly-6Clow monocytes/macrophages. Excessive inflammation 
disrupts the balance between the two phases, impairs infarct healing, and contributes to left ventricle 
remodeling and heart failure. Lipoprotein-associated phospholipase A2 (Lp-PLA2), a member of the 
phospholipase A2 family of enzymes, produced predominantly by leukocytes, participates in host defenses 
and disease. Elevated Lp-PLA2 levels associate with increased risk of cardiovascular events across 
diverse patient populations, but the mechanisms by which the enzyme elicits its effects remain unclear. 
This study tested the role of Lp-PLA2 in healing after MI. 
Methods and Results: In response to MI, Lp-PLA2 levels markedly increased in the circulation. To test 
the functional importance of Lp-PLA2, we generated chimeric mice whose bone marrow-derived 
leukocytes were Lp-PLA2-deficient (bmLp-PLA2–/–). Compared to WT controls, bmLp-PLA2–/– mice 
subjected to MI had lower serum levels of inflammatory cytokines TNFα, IL-1β and IL-6, and decreased 
number of circulating inflammatory myeloid cells. Accordingly, bmLp-PLA2–/– mice developed smaller 
and less inflamed infarcts with reduced numbers of infiltrating neutrophils and inflammatory Ly-6Chigh 
monocytes. During the later, reparative phase, infarcts of bmLp-PLA2–/– mice contained  Ly-6Clow 
macrophages with a skewed M2-prone gene expression signature, increased collagen deposition, fewer 
inflammatory cells, and improved indices of angiogenesis. Consequently, the hearts of bmLp-PLA2–/– mice 
healed more efficiently, as determined by improved left ventricle (LV) remodeling and ejection fraction.
Conclusions: Lp-PLA2 augments the inflammatory response after myocardial infarction and antagonizes 
healing by disrupting the balance between inflammation and repair, providing a rationale for focused 
study of ventricular function and heart failure after targeting this enzyme acutely in MI.
2
Myocardial infarction (MI) is a leading cause of death worldwide1. Although the case fatality rate of MI 
has declined, survival with development of long-term left ventricular dysfunction due to cumulative 
ischemic myocardial damage has added to the growing epidemic burden of chronic heart failure.  The 
human, social, and economic consequences of chronic ischemic cardiomyopathy present a major 
challenge and unmet medical need. Patients who initially survive MI must overcome a major obstacle: 
ischemia damages the heart, and effective cardiac repair likely requires a precise balance between 
removal of debris and formation of a scar that is compatible with heart function. MI survivors frequently 
develop heart failure; while many therapeutics in current use have proven beneficial, the high residual 
morbidity and mortality presents an urgent problem that requires a better understanding of the disease’s 
pathophysiology.
Over the last several years, neutrophils, monocytes and macrophages have emerged as consequential to 
the inflammatory and healing process that occurs after MI2. We now understand that ischemic injury 
triggers the accumulation of these myeloid cells in the infarcted myocardium3, 4. Shortly after onset of 
ischemia, large numbers of neutrophils and inflammatory Ly-6Chigh monocytes infiltrate the infarcted 
myocardium and produce IL-1β, IL-6, and TNFα. Within 4-5 days, Ly-6Chigh monocytes give rise to 
Ly-6Clow reparative macrophages3, which potentiate healing via VEGF, TGFβ, and IL-10. The two phases 
comprising inflammatory Ly-6Chigh monocyte recruitment and reparative Ly-6Clow macrophage 
differentiation are essential to post-MI recovery; their perturbation (i.e., in the context of co-morbidities) 
leads to impaired heart function and heart failure3, 4.
Lipoprotein-associated phospholipase A2 (Lp-PLA2), a member of the phospholipase A2 family of 
enzymes, hydrolyses glycerophospholipids. The ensuing enzymatic reactions frequently generate 
metabolic signaling molecules with a multitude of biological actions. For example, by hydrolysing 
phosphotidylcholine at C2 of the glycerol backbone, Lp-PLA2 produces lysophosphatidylcholine 
(lysoPC)5, which fosters oxidative stress, affects vascular smooth muscle cell proliferation, and increases 
tissue accumulation of macrophages6. A number of observational studies showed that Lp-PLA2 levels 
correspond with future cardiovascular events such as acute myocardial infarction and sudden cardiac 
death.7-9 While preliminary studies reported reduced development of advanced coronary atherosclerosis10 
or stabilization of the necrotic core size11 with selective inhibition of Lp-PLA2 by the inhibitor darapladib, 
two recently completed phase III trials did not provide evidence in favor of inhibiting Lp-PLA2 in 
cardiovascular disease12. Neither study focused on left ventricular function nor chronic heart failure 
endpoints. Moreover, it remains unclear whether Lp-PLA2 participates in the inflammatory and reparative 
phases that characterize the innate immune response shortly after MI; these pathways likely influence left 
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ventricular remodeling and the development of chronic ischemic cardiomyopathy.  This study sought to 
evaluate whether Lp-PLA2 participates in infarct healing and HF after MI.
Methods
For further details, see the online Supplemental Material.
Animals and animal experiments. 8-10 weeks old Female C57BL6/J (WT) were purchased from the 
Jackson Laboratory (Bar Harbor, ME). Lp-PLA2-deficient mice (Lp-PLA2–/– ) were kindly provided by 
Glaxosmithkline Pharmaceuticals Ltd (King of Prussia, PA 19112). All protocols were approved by the 
Animal Review Committee at Massachusetts General Hospital. C57BL6/J mice were lethally irradiated 
and reconstituted with WT and Lp-PLA2–/–  bone marrow to generate respective chimeric mice.  The 
chimeras had normal leukocyte counts and exhibited no obvious abnormalities, consistent with the Lp-
PLA2-deficient mice13. Myocardial infarction (MI) was induced by permanent ligation of the left anterior 
descending artery.  We observed no differences in mortality between the groups.
Lp-PLA2/PAF acetyl-hydrolase activity assay. The PAF hydrolase activity assay was performed as 
previously described14 with modifications using [3H]PAF (Platelet Activating Factor, 1-O-Hexadecyl-
[Acetyl-3H(N)]-, Hexadecyl PAF) as a substrate. Unlabeled PAF (1-O-Hexadecyl-2-O-acetyl-sn-
glycero-3-phophorylcholine) was purchased from Enzo Life Sciences, 1-O-Hexadecyl-2-O-
[Acetyl-3H(N)]-, Hexadecyl PAF, [acetyl-3H]-, (250µCi (9.25MBq) was purchased from Perkin Elmer, 
and Bio-Safe II was purchased from Research Products International Corp., Mount Prospect, IL.
Histology. Murine hearts were embedded in Tissue-Tek O.C.T compound (Sakura Finetek) and prepared 
for sectioning and staining. 
Flow cytometry and flow assisted cell sorting. Antibodies used for flow cytometry are listed in the 
online Supplemental Material. Data were acquired on a BD LSRII and analyzed with FlowJo. Cells were 
sorted with BD AriaII.  
Reverse transcription PCR. RNA was isolated from sorted cells with the RNeasy Micro Kit (Qiagen). 
Quantitative real-time TaqMan PCR was run on a 7500 PCR thermal cycler (Applied Biosystems).
Magnetic resonance imaging (MRI). MRI was carried out on days 1 and 21 after permanent coronary 
ligation as described perviously3. We obtained cine images of the left ventricular short axis by using a 7 
Tesla horizontal bore Pharmascan (Bruker) and a custom-built mouse cardiac coil (Rapid Biomedical). 
Late gadolinium enhancement was performed on day 1 to determine infarct size. Acquisition was done as 
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described previously15. Images were analyzed using the software Segment (http://segment.heiberg.se).The 
end-diastolic volume (EDV), end-systolic volume (ESV), ejection fraction (EF), left ventricle volume 
(LVM), heart rate and cardiac output (CO) were measured.
Statistics: Results are shown as mean ± SEM. Unpaired Student’s t-test was applied to evaluate 
differences between two groups. One-way ANOVA with post-hoc Tukey’s multiple comparisons test was 
performed when comparing more than two groups between days, because different mice were sacrificed 
on each time points for organ harvest. P-values of 0.05 and less denote significant changes.
Results
Expression of Lp-PLA2 after MI and its role on healing
To elucidate whether Lp-PLA2 participates in healing after MI, we first measured Lp-PLA2 expression 
and serum activity in steady state and after MI. Lp-PLA2 mRNA expression by RT-PCR increased in the 
infarcts of wild type (WT) mice as early as 1 day after MI (Fig. 1A), suggesting Lp-PLA2 may participate 
in myocardial ischemic injury. Concordantly, Lp-PLA2 activity was also increased shortly after MI (Fig. 
1B).  To define the role of Lp-PLA2 in hematopoietic cells in the pathophysiology of acute MI, we 
generated chimeric mice by irradiating and reconstituting WT mice with bone marrow either from WT or 
Lp-PLA2−/− (bmLp-PLA2−/−) mice. In comparison to WT mice, bmLp-PLA2−/− mice had lower Lp-PLA2 
activity at steady state, and this activity did not change after MI (Fig. 1B). These findings establish 
leukocytes as major sources of Lp-PLA2 in response to MI. We then evaluated infarct healing and 
demonstrated a significant decrease in infarct size in bmLp-PLA2−/− mice 7 days after MI compared to WT  
(Fig. 1C, D).  
Lp-PLA2 influences systemic inflammation
Coronary occlusion stimulates an inflammatory response characterized by cytokine and chemokine 
production, and leukocyte recruitment to the heart. Because Lp-PLA2 participates in inflammation, we 
assessed the effect of Lp-PLA2 deficiency after MI. Serum concentrations of inflammatory cytokines 
TNFα, IL-1β and IL-6 increased dramatically in WT mice on day 1 after MI, and eventually declined to 
undetectable amounts on day 7. In contrast, bmLp-PLA2−/− mice showed only moderately elevated TNFα 
and IL-6, and negligibly increased IL-1β, demonstrating a diminished inflammatory response in the 
absence of Lp-PLA2 (Fig. 2A). Time-course profiling of circulating leukocytes after MI revealed that both 
WT and bmLp-PLA2−/− mice augmented inflammatory myeloid cells (neutrophils and Ly-6Chigh 
monocytes), but compared to WT mice, bmLp-PLA2−/− mice had fewer neutrophils and Ly-6Chigh cells in 
blood at days 3 and 7, indicating Lp-PLA2 contributes to the systemic inflammation after MI (Fig. 2B, C).
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Lp-PLA2 impairs the appearance of reparative macrophages
The myocardium displays a biphasic monocyte and macrophage response during MI3, 4. In the first phase, 
inflammatory Ly-6Chigh monocytes infiltrate the ischemic myocardium from the blood and participate in 
inflammation. In the second phase, reparative Ly-6Clow macrophages contribute to collagen deposition 
and scar formation. We profiled leukocytes in the myocardium in the steady state and 1, 3 and 7 days after 
MI in both WT and bmLp-PLA2−/− mice. The infarcts of both strains accumulated neutrophils, which 
peaked on day 1, Ly-6Chigh monocytes, which peaked on day 3, and Ly-6Clow macrophages, which peaked 
on day 7 (Fig. 3A, B). This finding agrees with our previous observations3, 4. Yet, for nearly every peak, 
infarcts of bmLp-PLA2−/− mice accumulated only half the number of cells (neutrophils on day 1 and 
Ly-6Chigh monocytes on day 3) compared to WT controls, consistent with our observations in the blood 
(Fig. 2), and affirming that Lp-PLA2 aggravates inflammation. 
 
Aside from determining the number of cells that accumulate (quantity), macrophage activity (quality) is 
an essential measure of the cells’ impact on inflammation and repair. We asked whether Lp-PLA2 shapes 
macrophage function by measuring expression of signature M1/M2 genes in sorted cardiac macrophages. 
In comparison to WT macrophages, Lp-PLA2–/– macrophages exhibited higher expression of mRNAs that 
encode M2-associated genes (Arg, IL-10, CD36, Fizz) and lower levels of those corresponding to M1-
associated genes (MMP-3, MMP-9, TLR9, TLR4) (Fig. 3C). These data are consistent with the idea that 
lysophosphotidylcholine, a product of Lp-PLA2, potentiates an M1-like macrophage phenotype.16 
Together, these data show that Lp-PLA2 promotes recruitment of inflammatory myeloid cells and delays 
the appearance of reparative macrophages in the ischemic myocardium.
Lp-PLA2 retards healing after myocardial infarction
The differences in leukocyte recruitment between WT and bmLp-PLA2−/− mice prompted us to determine 
whether the absence of Lp-PLA2 affects the repair of the ischemic myocardium. To this end, we profiled 
myeloid cell infiltration, extracellular matrix deposition, neovascularization, and smooth muscle cell 
accumulation by immunohistochemistry (Fig. 4). Compared with WT controls, the myocardium of bmLp-
PLA2−/− mice accumulated fewer myeloid CD11b+ cells, indicating less severe inflammation. Infarcts of 
bmLp-PLA2−/− mice also had larger regions of extracellular matrix deposition, as evidenced by higher 
percentage of collagen I+ areas (24% versus 32%,), larger CD31+ areas (5% vs 11%), suggesting 
improved neovascularization of the heart, but no changes in the number of  smooth muscle actin+ 
myofibroblasts (α-SMA+ area). Collectively, the results of histologic examination demonstrate more 
effective healing in the absence of Lp-PLA2. These results demonstrate that Lp-PLA2 inhibits the 
resolution of inflammation after MI.
Improved heart function in the absence of Lp-PLA2
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To test whether inflammation mediated by Lp-PLA2 after MI translated to impaired heart function, we 
performed magnetic resonance imaging (MRI) in vivo in WT and bmLp-PLA2−/− mice. In the steady state, 
we detected no differences in cardiac function between WT and bmLp-PLA2−/− mice. After permanent 
coronary artery ligation, the end-diastolic volume (EDV) and end-systolic volume (ESV), ejection 
fraction (EF), left ventricle volume (LVM), heart rate and cardiac output (CO) were measured in 
individual mice on day 1 and day 21 after MI. Late gadolinium enhancement was performed on day 1 to 
determine infarct size (Fig. 5A, B and Table 1). The infarct sizes were similar on day 1 in both groups, 
excluding a potential surgical bias (Fig. 5B).  Although LVM increased similarly between the two groups 
on day 21, increased EDV was only observed in WT mice, indicating more favorable remodeling in mice 
lacking Lp-PLA2. Moreover, compared with day 1, EF at day 21 diminished in WT mice but increased 
modestly in bmLp-PLA2−/− mice, suggesting improved recovery of heart function in the absence of Lp-
PLA2. Overall, the data show that Lp-PLA2 aggravates LV remodeling and impairs LV function after MI.
Discussion
Recruitment of neutrophils and Ly-6Chigh monocytes into the infarcted myocardium and the subsequent 
generation of reparative macrophages from Ly-6Chigh monocytes contribute to necrotic debris clearance, 
matrix deposition, granulation tissue formation, and angiogenesis. Perturbations in the inflammatory 
response impair infarct healing and promote heart failure17-19. This study shows that deficiency of Lp-
PLA2 on hematopoietic cells attenuates systemic inflammation after MI, impairs leukocyte infiltration 
into infarcts, and enhances generation of reparative Ly-6Clow macrophages, leading to less adverse LV 
remodeling and improved recovery of LV function. Together, the data show that Lp-PLA2 modulates 
inflammation after MI and suggest that targeting of Lp-PLA2 might lessen LV dysfunction and the 
development of chronic heart failure following myocardial infarction.
Monocyte-derived macrophages can produce substantial Lp-PLA220, and in the mouse Lp-PLA2 is 
expressed almost exclusively by myeloid cells (www.immgen.org). Previous studies have identified 
macrophage Lp-PLA2 expression at both the mRNA and protein levels in human and rabbit aortic 
lesions21.  Plaques with characteristics of vulnerable and ruptured atheromata, but not early lesions, 
contain abundant Lp-PLA222. Therefore, extensive efforts have been taken to prevent atherosclerosis-
related coronary heart disease by inhibiting Lp-PLA2 and thus promoting plaque stability12. But Lp-PLA2 
may participate in coronary heart disease by modulating inflammation independent of effects on the 
plaque itself. For example, our data showed that Lp-PLA2 rose dramatically during MI. As a 
phospholipase, increased Lp-PLA2 hydrolyzes phospholipids of oxidatively damaged cells or 
lipoproteins.  Lp-PLA2 hydrolyzes oxidized phosphatidylcholine, generating lysoPC and oxidized fatty 
acids that are capable of acting as monocyte chemoattractants as well as maintaining macrophages in a 
pro-inflammatory phenotype6, 16, 23.  Lp-PLA2 can also contribute to inflammation by interfering with 
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phagocytic clearance of apoptotic cells, e.g. neutrophils, via cleavage and removal of oxidized 
phosphatidylserine, a known “eat-me” signal24. Consistent with this hypothesis, we found that bmLp-
PLA2−/− mice had milder inflammatory responses as well as fewer neutrophils and Ly-6Chigh monocytes 
accumulating in the myocardium. This reduced number of inflammatory leukocytes ameliorated adverse 
LV remodeling and improved heart function recovery. Therefore, our data strongly support a role for Lp-
PLA2 in increased risk of heart failure by directly promoting systemic and local myocardial inflammatory 
responses after MI, functions distinct from effects on the atherosclerotic plaques.  Our experiments, 
performed with bone marrow chimeras, demonstrate an effect on MI healing with a ~80% knockdown of 
Lp-PLA2, indicating this is a sufficient reduction to elicit positive effects. Future studies will need to 
elucidate in more detail the full scope of Lp-PLA2 function not only on leukocyte behavior, but also on 
effects attributed to other cells in the heart, such as fibroblasts and endothelial cells.
Recently, two large multi-center phase III trials completed evaluation of the Lp-PLA2 inhibitor darapladib 
on the reduction of cardiovascular adverse events in over 28,000 patients with documented coronary heart 
disease. These two complementary trials covered both chronic and acute coronary heart disease and 
evaluated traditional coronary heart disease endpoints. Thus, these studies did not formally focus on LV 
function or long-term development of heart failure25, 26. The Stabilization of pLaques usIng Darapladib-
Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial enrolled patients within 30 days of acute 
coronary syndrome (ACS) and the STabilization of Atherosclerotic plaque By Initiation of darapLadIb 
TherapY (STABILITY) trial enrolled patients with stable chronic coronary heart disease. Despite 
promising preclinical results10, both clinical trials concluded that direct inhibition of Lp-PLA2 with 
darapladib failed to reduce major adverse cardiovascular events12, 27. Crucially, the trials did not test 
whether blockade of Lp-PLA2 per se was beneficial: patients receiving darapladib or placebo were 
already receiving up to 4 different therapeutics against heart disease, including statins and ACE inhibitors. 
The trials therefore showed that under the specific parameters of the study, darapladib did not provide 
benefit above that afforded by current treatment regimens.
Our results provide an alternative explanation as to why the clinical trials might not have improved the 
tested end-points. Our data show that, as early as day 1 after MI, expression of Lp-PLA2 was increased. In 
the absence of Lp-PLA2, inflammatory leukocyte recruitment was blunted, yielding a smaller 
inflammatory response that correlated with improved healing and heart function 7 and 21 days later, 
respectively. Lp-PLA2 might elicit its most detrimental effects in the acute phase after MI. If so, blocking 
the enzyme earlier than the SOLID or STABILITY trials might benefit endpoints related to LV function. 
Several human studies have shown data in support of the idea that healing of the infarcted myocardium 
involves the biphasic accumulation of monocytes and macrophages. In one study, a cohort of 36 patients 
monitored over two weeks after MI demonstrated a peak of circulating inflammatory CD16− monocytes 
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on day 2.6 after MI, followed by another peak of CD16+ monocytes on day 4.8.19 Because CD16– 
monocytes resemble inflammatory Ly-6Chigh monocytes whereas CD16+ monocytes (and in particular 
CD16+ CD14dim) resemble Ly-6Clow monocytes, these findings suggest that acute inflammation may 
likewise peak in humans within one week after MI. Immediate inhibition of Lp-PLA2 might be the 
optimal time window for improving outcomes related to LV function. The SOLID trial, which enrolled 
patients within 30 days, did not test whether patients receiving darapladib within the first 3 days post MI 
benefited from treatment. Hence, the clinical trial findings do not argue against the role of Lp-PLA2 in 
inflammation after MI.
In summary, the data demonstrate that Lp-PLA2 regulates the host response after MI through modulation 
of inflammation. By enhancing inflammation and impairing repair, the induced Lp-PLA2 negatively 
regulates recovery of LV function. In addition to stimulating atherosclerotic plaque vulnerability, the 
effect of Lp-PLA2 after MI reveals a novel role of this enzyme in modulating the myocardial response to 
ischemic injury.  These mechanistic insights have implications for developing effective therapeutics 
against ischemic cardiomyopathy and chronic heart failure post MI. 
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Figure Legends
Figure 1: Lp-PLA2 activity and mRNA expression during myocardial infarction.  A, mRNA levels 
quantified by Realtime PCR in wild-type (WT) mice at the indicated time points after MI. Day 0 
represents the steady state mice. Results are presented as mean ± SD, ** p ≤ 0.01, n = 5-10 per group. B, 
Plasma Lp-PLA2 activity in chimera WT and bmLp-PLA2–/– mice at steady state  and in bmLp-PLA2–/– 
mice at indicated time points after MI. ** p ≤ 0.01, n = 5-10 per group. C, Quantification of infarct size 
on day 1 and 7 after MI in WT and bmLp-PLA2–/– mice (left). * p ≤ 0.05, n = 4-6 per group. D, 
Representative images of infarct size on day 7 after MI were shown in both WT and bmLp-PLA2–/– mice.
11
Figure 2: LP-PLA2 moderately affects systemic inflammation. A, ELISA analysis of plasma levels of 
TNFα, IL-1β and IL-6 in wild-type (WT) and bmLp-PLA2–/– mice at the indicated time points after MI. B, 
Representative flow cytometric images of leukocyte profiling of blood in wild-type (WT) and bmLp-
PLA2–/– mice, C, Quantification of total leukocytes, neutrophils, Ly-6Chigh monocytes, Ly-6Clow 
monocytes in the blood. Results in one of three experiments with similar patterns are presented as mean ± 
SEM, * p ≤ 0.05, ** p ≤ 0.01 (WT vs. bmLp-PLA2–/–) vs.  n = 5 per group. 
Figure 3: Attenuated inflammatory response in bmLp-PLA2–/– myocardial infarct tissue. A, 
Representative images for flow cytometric analysis of MI tissue cell suspensions at the indicated time 
points after MI in WT and bmLp-PLA2–/– mice.  B, Flow cytometry based quantification of neutrophil, 
monocyte and MΦ (macrophage) numbers in MI tissue of WT versus bmLp-PLA2–/– mice before and 1, 3, 
and 7 days post MI. Results in one of three experiments with similar patterns are presented as mean ± 
SEM, * p ≤ 0.05, n = 4 per group. C, Gene expression profiling of WT and bmLp-PLA2–/– macrophages 
sorted from MI tissue 7 days after permanent LAD ligation. Results are presented as mean ± SEM percent  
change of marker expression in Lp-PLA2–/– compared to WT control mice, * p ≤ 0.05, ** p ≤ 0.01, n = 5 
per group.
 
Figure 4: Improved cardiac remodeling in bmLp-PLA2–/– mice 7 days after myocardial infarction. 
Immunohistochemical staining of MI tissue for CD11b, Collagen 1 (Col1), CD31, and non-vascular 
smooth muscle alpha actin (SMA) in wild-type (WT) and bmLp-PLA2–/– chimeric mice 7 days post MI 
Quantification of 10 randomly selected fields of view per mouse (5 mice). Results are presented as mean 
± SEM, * p ≤ 0.05, *** p ≤ 0.001, n =50 fields of view per group.  
Figure 5: Lp-PLA2 aggravates LV dysfunction after myocardial infarction. 
A, Representative MRI images with late gadolinium enhancement  (left panels) on day 1 after permanent 
LAD ligation, and end-systole (middle panels) and end-diastole (right panels) on day 21 of infarcted 
hearts from WT and bmLp-PLA2–/– mice, respectively. B, Quantification of individual changes (∆) in heart  
parameters from day 1 to day 21 post MI (day 21 – day 1). Results are presented as mean ± SD percent 
change of marker expression in WT and  bmLp-PLA2–/– mice, respectively. * p ≤ 0.05, n  ≥7 per group.
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